Colon Cancer Clinical Trials in Los Angeles, California
11 recruitingLos Angeles, California
Showing 1–11 of 11 trials
Recruiting
Phase 1Phase 2
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
Colorectal, CancerOvarian CancerLung Cancer+17 more
A2 Biotherapeutics Inc.474 enrolled12 locationsNCT06051695
Recruiting
Phase 1
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of CBI-1214 T Cell Engager in Participants With Advanced or Metastatic MSS/MSI-L Colorectal Cancer
Colorectal, CancerColon CancerCRC+4 more
Cartography Biosciences80 enrolled8 locationsNCT07321106
Recruiting
Phase 1
A Study of PHN-012 in Patients With Advanced Solid Tumors
Pancreatic CancerColon CancerAdvanced Cancer+2 more
Pheon Therapeutics165 enrolled20 locationsNCT07127874
Recruiting
Phase 2Phase 3
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
Stage III Colon Cancer
NRG Oncology1,912 enrolled1061 locationsNCT05174169
Recruiting
Phase 1
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Metastatic Breast Carcinoma+37 more
National Cancer Institute (NCI)51 enrolled23 locationsNCT04704661
Recruiting
Phase 1
A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
Pancreatic CancerLung CancerColon Cancer+3 more
RasCal Therapeutics, Inc.134 enrolled3 locationsNCT04678648
Recruiting
Not Applicable
Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes
Liver CancerBiliary Tract CancerColon Cancer+76 more
Cedars-Sinai Medical Center360 enrolled1 locationNCT04907643
Recruiting
EXoPERT EMERALD Clinical Study
Breast CancerPancreatic CancerOvarian Cancer+2 more
EXoPERT1,400 enrolled9 locationsNCT07186296
Recruiting
Phase 1Phase 2
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
Triple-Negative Breast CancerColorectal, CancerLung Cancer+14 more
A2 Biotherapeutics Inc.240 enrolled10 locationsNCT06682793
Recruiting
Phase 2
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
Pancreatic CancerGastric CancerLung Cancer+15 more
Apollomics Inc.497 enrolled35 locationsNCT03175224
Recruiting
Phase 1
A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors
Colon CancerMetastatic Colon Cancer
Sapience Therapeutics130 enrolled11 locationsNCT05848739